'Major Advance': Sotorasib Benefit Persists in KRAS+ NSCLC
The first-in-class KRAS inhibitor showed durable benefit in some patients, but emergence of early resistance requires new combination therapies, investigators say.
Medscape Medical News
source https://www.medscape.com/viewarticle/972067?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/972067?src=rss
Comments
Post a Comment